All In Biotech

Drug Trial Radar · NCT02103283

A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)

Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)

Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

5

Actual

Start

Oct 2014

Primary completion

Aug 2016

Study completion Aug 2016

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Apr 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1 Study to evaluate the Safety of teprotumumab in Patients with Diabetic Macular Edema.

Conditions

  • Diabetic Macular Edema

Interventions

  • TeprotumumabDrug

    Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of RV001in subjects with Diabetic Macular EdemaTime frame: Change from Baseline to Week 9

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • David S Boyer

    Beverly Hills, California

  • David A Eichenbaum, MD

    St. Petersburg, Florida

  • Diana Do, MD

    Omaha, Nebraska

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.